Implementing NGS‑Based Assays in GxP Environments: From Regulatory Expectations to Operational Execution

Regulatory frameworks for the use of next‑generation sequencing (NGS) in GxP environments are now clearly defined, shifting the industry’s focus from adoption to execution. As discussed in a previous article, guidance such as ICH Q5A(R2)¹ outlines what compliant use of NGS‑based assays looks like in regulated product characterization and biosafety testing. 

With this regulatory context established, biopharmaceutical organizations now face the practical challenge of implementing NGS in routine, GxP‑compliant operations. This article examines how those expectations are addressed in practice, focusing on Computerized System Validation (CSV), multi‑instrument and multi‑site workflows, and the validation of wet‑lab protocols and bioinformatics pipelines. 

Core Challenges of Implementing NGS in GxP Environments 

Although regulatory frameworks now define clear expectations for the use of NGS‑based assays in GxP environments, the challenge lies in implementation within routine, regulated operations. Regulatory acceptance establishes what compliant use should achieve, but it does not prescribe how organizations should operationalize NGS within validated workflows. 

This implementation challenge becomes evident as NGS moves from exploratory or limited use into broader application across product characterization and biosafety testing. Unlike many classical assays, NGS workflows span multiple technologies, disciplines, and systems, creating dependencies that extend beyond the assay itself and introduce additional coordination, validation, and lifecycle considerations. 

Challenge 3: GxP Validation of Wet‑Lab Protocols and Bioinformatics Pipelines 

Validating NGS‑based assays in GxP environments requires coordinated control over both wet‑lab protocols and downstream bioinformatics pipelines. Although these components are often developed independently during early adoption, GxP use requires that they be validated together as a unified analytical workflow.  

Wet‑lab validation must demonstrate that sample preparation, sequencing runs, and quality controls perform consistently and reproducibly under defined conditions. Because variability can be introduced at multiple stages, including library preparation, sequencing chemistry, and instrument performance, maintaining controlled execution across studies and time is more complex than for many classical assays.  

Bioinformatics pipelines add further validation complexity. Data processing typically involves multiple algorithmic steps, reference datasets, and configurable parameters that influence analytical outcomes. In GxP environments, organizations must demonstrate that pipelines generate accurate and reproducible results for their intended use and that changes to software, algorithms, or reference data are assessed and controlled. 

Together, these requirements highlight a defining characteristic of NGS‑based assays: analytical performance depends on both laboratory execution and computational processing, increasing the scope and depth of validation activities compared with traditional methods. 

Establishing a Sustainable, Validated NGS Operating Model 

Addressing CSV, workflow scale, and assay validation individually is necessary, but long‑term success depends on integrating these elements into an operating model that can sustain compliance as NGS workflows evolve. 

A sustainable model requires standardized workflows that can be executed consistently across instruments, sites, and teams, supporting reproducibility over time. It also requires controlled configurations so that instruments, software versions, analytical parameters, and reference data remain governed within a validated state. Audit‑ready reporting is essential to ensure that results, data lineage, and supporting evidence can be reviewed efficiently and defended during inspections without ad hoc reconstruction. Finally, sustainable execution depends on effective lifecycle change management, including impact assessment and controlled revalidation as workflows, pipelines, or infrastructure change. 

Together, these requirements define the foundation for a validated NGS operating model that supports current regulatory expectations while enabling future expansion.  

Enabling Operational Execution with Genedata

Translating regulatory expectations into sustainable, day‑to‑day NGS operations requires systems designed specifically for regulated environments. Beyond addressing individual challenges, organizations need an execution framework that can manage complexity while maintaining validation status as workflows evolve. 

Genedata develops enterprise software solutions purpose‑built to support data‑intensive, regulated workflows across biopharmaceutical R&D and manufacturing. With domain expertise spanning science, informatics, and quality, Genedata supports organizations in operationalizing NGS‑based assays in alignment with GxP requirements.